RESEARCH ARTICLE

1

6

10

17

20

- Antigen-specific T cell responses following single and co-2
- administration of tick-borne encephalitis, Japanese 3
- encephalitis, and yellow fever virus vaccines: Results from an 4
- open-label, non-randomized clinical trial-cohort 5
- 7 David Wullimann¹, John Tyler Sandberg¹, Mira Akber¹, Marie Löfling¹, Sara Gredmark-
- 8 Russ^{1,2}, Jakob Michaëlsson¹, Marcus Buggert¹, Kim Blom^{1,3}, Hans-Gustaf Ljunggren^{1*}
- 9 *hans-gustaf.ljunggren@ki.se
- 11 ¹ Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska
- 12 Institutet, Stockholm, Sweden
- 13 ² Department of Infectious Diseases, Karolinska University Hospital, Stockholm,
- 14 Sweden
- 15 ³ Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet,
- Stockholm, Sweden 16
- **Short title:** 18
- 19 T cell responses following co-administration of flavivirus vaccines
- 21 **Funding:**
- 22 This work was supported by the Swedish Research Council (2015-02499, 2020-01365;
- 23 HGL), the Swedish Foundation for Strategic Research (SB12-0003; HGL), Region
- 24 Stockholm (CIMED 2020-2022; HGL and KB), Karolinska Institutet (HGL), and KID PhD
- student funding grants from Karolinska Institutet for DW and JTS (HGL). The funders had NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 25

26 no role in study design, data collection and analysis, decision to publish, or preparation 27 of the manuscript. 28 **URL** to website: 29 30 https://ki.se/en/medh/hans-gustaf-ljunggren-group-immune-responses-to-human-31 virus-infections-and-cancer 32 33 **Competing interest:** 34 The authors have declared no competing interest exists. 35 36 **Abbreviations:** 37 Ab antibody 38 ΑE adverse events activation-induced marker 39 AIM С 40 capsid dengue virus 41 **DENV DMSO** Dimethyl sulfoxide 42 Ε 43 envelope 44 **JEV** Japanese encephalitis virus 45 nAb neutralizing antibody 46 NS5 non-structural protein 5 peripheral blood mononuclear cells 47 **PBMC** Staphylococcal enterotoxin B 48 SEB 49 **TBEV** tick-borne encephalitis virus

50	YFV	yellow fever virus
51	WNV	West Nile virus
52	ZIKV	Zika virus
53		

Abstract

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Background Flavivirus infections pose a significant global health burden, highlighting the need for safe and effective vaccination strategies. Co-administration of different vaccines, including licensed flavivirus vaccines, is commonly practiced providing protection against multiple pathogens while also saving time and reducing visits to healthcare units. However, how co-administration of different flavivirus vaccines de facto affects immunogenicity, particularly with respect to T cell responses, is only partially understood. Methods and findings Antigen-specific T cell responses were assessed in study participants enrolled in a previously conducted open-label, non-randomized clinical trial. In the trial, vaccines against tick-borne encephalitis virus (TBEV), Japanese encephalitis virus (JEV), or yellow fever virus (YFV) were administered either individually or concomitantly in different combinations in healthy study participants. Peripheral blood samples were collected before vaccination and at multiple time points afterward. To analyze antigen-specific CD4+ and CD8+ T cell responses, PBMCs were stimulated with overlapping peptide pools from TBEV, JEV, YFV, and Zika virus (ZIKV) envelope (E), capsid (C), and nonstructural protein 5 (NS5) viral antigens. A flow cytometry-based activation-induced marker (AIM) assay was used to quantify antigen-specific T cell responses. The results revealed remarkably similar frequencies of CD4+ and CD8+ T cell responses, regardless of whether vaccines were administered individually or concomitantly. In addition, administering the vaccines in the same or different upper arms did not markedly affect T cell responses. Finally, no significant cross-reactivity was observed between TBEV, JEV, and YFV vaccines, nor with related ZIKV-specific antigens. Conclusions TBEV or JEV vaccines can be co-administered with the live attenuated YFV vaccine without any markedly altered antigen-specific CD4+ and CD8+ T cell responses to the

respective flaviviruses. Additionally, the vaccines can be delivered in the same or

different upper arms without any significant influence on the T cell response. From a broader perspective, these results provide valuable insights into the outcome of immune responses following simultaneous administration of different vaccines for different but related pathogens.

83

84

85

86

87

Author summary

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

Why was this study done?

- The World Health Organization recently declared a global initiative to control arboviral diseases. Many of these are caused by pathogenic flaviviruses, most transmitted by mosquitos and other arthropod vectors such as ticks.
- Vaccination is a key intervention for diseases caused by flaviviruses.
- Co-administration of different vaccines, including currently licensed flavivirus vaccines, is commonly practiced.
 - Co-administration of vaccines saves time and reduces the number of visits to healthcare facilities and vaccine clinics.
 - Cellular immune responses have not been thoroughly evaluated upon coadministration of currently licensed flavivirus vaccines, including yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JEV) vaccines.

What did the researchers find?

- The magnitude and specificity of CD4+ and CD8+T cell responses to virusspecific antigens remained largely unchanged by the concomitant delivery of the studied flavivirus vaccines.
- Concomitant delivery of vaccines in the same or different upper arms of the study participants had minimal impact on CD4+ and CD8+ T cell responses.
- The studied vaccines maintained distinct CD4+ and CD8+ T cell reactivity across their respective viral antigens without generating any significantly detectable cross-reactivity to each other or ZIKV-antigens.

What do these findings mean?

116

117

118

119

Along with recently published data from the present study cohort, coadministration of three commonly used current licensed flavivirus vaccines is feasible without increasing the risk of adverse events or significantly affecting the development of either neutralizing antibodies (nAbs) or T cell responses against the respective viral antigens.

Introduction

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and Japanese encephalitis virus (JEV) all belong to the *Flaviviridae* family of enveloped positive-sense RNA viruses [1]. These viruses pose major global health challenges, affecting both the inhabitants of endemic areas (around one-third of the world's population) and travelers to these regions [2-4]. Infections with these viruses are associated with significant morbidity and numerous fatalities each year [5, 6]. No specific treatment for the diseases exists, though the development of antiviral drug candidates in the field is an active area of research [7]. A range of licensed flavivirus vaccines are currently available, including vaccines against YFV, TBEV, and JEV [8, 9]. These are frequently used to prevent disease among residents of endemic areas and travelers visiting these regions. In addition, several newer vaccines have been successful in late-phase clinical trials [10]. Safe and effective vaccine administration strategies are crucial [6]. While rigorous clinical trials have assessed the safety and immunogenicity of most currently approved vaccines, more limited data exist regarding administration strategies and the interactions between different flavivirus vaccines including the currently studied live attenuated YFV vaccine as well as inactivated TBEV and JEV vaccines [11]. To address this knowledge gap, we conducted an open-label, non-randomized clinical trial to assess the safety and serological response following concomitant delivery of commonly used licensed flavivirus vaccines [12]. The trial cohort included healthy adult volunteers who were vaccinated with either YFV and TBEV vaccines, YFV and JEV vaccines, or with the three respective vaccines alone. Half of the co-vaccinated participants received vaccines in the same upper arm, while the other half received the vaccines in different upper arms. Blood samples were collected before vaccination and at multiple time points afterward. Safety, as well as binding and nAb responses, were evaluated in detail [12]. However, the study did not assess antigen-specific T cell responses, an important part of the flavivirus immune response and induction of protective immunity [13].

150

151

152

153

154

155

156

157

158

159

160

In this study, we stimulated cryopreserved PBMCs from the above-mentioned clinical trial cohort with overlapping sets of peptides from TBEV, JEV, YFV, and ZIKV to identify antigen-specific CD4+ and CD8+ T cells. Stimulated PBMCs were assessed with an activation-induced marker (AIM) assay to determine the total T-cell response to major structural and non-structural flavivirus proteins, and to assess cross-reactivity. Collectively, the present study provides insights into antigen-specific T cell responses following vaccination with different types of flavivirus vaccines, whether the vaccines were administered individually or concomitantly delivered to study subjects. From a broader perspective, the present results add further insight into the vaccine-induced immune responses that protect against diseases caused by flaviviruses.

Methods

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

Cohort and clinical samples

The PBMC samples used in this study are based on a completed clinical trial, referred to below. The clinical trial was designed as an open label, non-randomized academic (non-Pharma sponsored) trial [12]. It was conducted to assess safety and serological responses to three currently licensed flavivirus vaccines administered either as single agents or concomitantly delivered. Inclusion criteria allowed the participation of healthy volunteers, 18 to 55 years of age, who sought protection from TBEV, JEV, or YFV or two of the three viruses (YFV and TBEV or YFV and TBEV). Participants were required to meet preset inclusion and exclusion criteria. All study volunteers had to sign informed consent documents in line with the ethical approval and clinical trial protocol. The trial was approved by the Stockholm Local Regional Ethical Committee (2017/1433-31/1) and the Swedish Medical Products Agency (5.1-2017-52376). It was registered and later on reported to the European database (EudraCT 2017-002137-32).

Vaccines

Study subjects included in the clinical trial were vaccinated with the following flavivirus vaccines: Stamaril (Sanofi), live attenuated YFV 17D strain produced in pathogen-free chick embryo cells; IXIARO (Valneva), an inactivated, alum-adjuvanted, Vero cellderived vaccine based on JEV strain SA14-14-2; FSME IMMUN (Pfizer), an inactivated, alum-adjuvanted, chick embryo cell-derived vaccine based on the TBEV Neudörfl strain [12]. All vaccines were obtained from Apoteket AB, Karolinska University Hospital, Solna, Sweden. Vaccinations were given in accordance with the clinical trial protocol and good clinical practice (GCP), with intervals for primary vaccinations as recommended in FASS (Pharmaceutical Specialties in Sweden): FSME IMMUN, three doses 0-, 1- and 5-month intervals; IXIARO, two doses, 0- and 1-month interval; Stamaril, one dose. For cohorts A1, A2, B1, B2, C, D, and E (for cohort description, see below), blood and serum were sampled before each vaccination and then on day 7 and

14 after each vaccination. Blood and serum were also sampled 30 days after the last vaccination (Fig 1A).

Study participants and cohorts

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

The clinical trial was initially designed to include 140 healthy volunteers [12]. Forty study participants were to receive both YFV and TBEV vaccines (cohort A). Twenty of these participants were to receive the vaccines in different upper arms (sub-cohort A1), and the other 20 in the same upper arm (sub-cohort A2). The next 40 study participants were to receive both YFV and JEV vaccines (cohort B). Similarly, 20 of these participants were to receive the vaccines in different upper arms (sub-cohort B1), and the other 20 in the same upper arm (sub-cohort B2). The remaining three cohorts consisted of 20 study participants per cohort and received either TBEV vaccine (cohort C), JEV vaccine (cohort D), or YFV vaccine (cohort E). Upon initiation of the clinical trial, a total of 161 healthy volunteers were screened for enrollment. 145 study participants were found eligible and enrolled in the trial. Among them, 43 participants were assigned to cohort A (A1, 23 participants; A2, 20 participants), 42 participants to cohort B (B1, 21 participants; B2, 21 participants), and 20 participants each to cohorts C, D, and E. Following enrollment three study participants dropped out from Cohort A1 and one study participant dropped out from each of cohorts B1, B2, and C. Hence, 139 study participants in total completed the trial. Throughout the trial, there were 13 missed visits out of a planned total of 1,150 visits [12].

Viral strain sequences and alignments

The viral vaccine strains used for multiple sequence alignments and peptide pools were obtained from UniProt; TBEV (Neudörfl, P14336), JEV (SA14-14-2, P27395), YFV (YFV-17D, P03314) and ZIKV (MR766, Q32ZE1). To determine percentage of homology between the different flaviviruses, multiple sequence alignment was performed with Clustal Omega [14].

Peptides

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

Individual overlapping peptides consisting of 15-mers (11 amino acids overlap) were synthesized as crude material and delivered solubilized in 100% DMSO at 20 mg/ml (Merck). Each peptide for TBEV, JEV, and YFV as well as for ZIKV (sequences corresponding to viral strain mentioned above) E, C, and NS5 antigens was pooled and diluted in phosphate-buffered saline (PBS)to 20% DMSO. For a full list of peptides, see S1 Data set.

Activation-induced marker (AIM) assay

To assess antigen-specific CD4+ and CD8+ T cell responses, a well-established AIM assay was used with slight modifications [15]. Briefly, PBMCs from study subjects (n=84) were thawed and resuspended in RPMI 1640 (Cytvia) supplemented with 10% Fetal bovine serum (Sigma-Aldrich), 1% Penicillin-streptomycin (Cytvia) and 1% L-glutamine (Sigma-Aldrich). One million cells per well were cultured in U-bottom 96-well plates (Corning) for 3 h at 37°C to rest. After resting, cells were stimulated with a mix containing the appropriate peptide pool (0.5 µg/ml), unconjugated anti-CD40, and anti-CXCR5 Abs. After a 14 h incubation at 37°C and 5% CO₂, the plate was centrifuged at 1,800 rpm for 3 min, and the supernatant was removed. The cells were transferred to V-bottom 96-well plates (ThermoFischer Scientific) and washed with PBS. Cells were stained for viability for 10 min, incubated with anti-CCR7 and anti-CX3CR1 at 37°C for 10 min, followed by the remaining fluorophore-conjugated Abs which were mixed with Brilliant Violet Buffer Plus (BD Biosciences) and FACS buffer (PBS with 2% FBS and 2 mM ethylenediaminetetraacetic acid [EDTA]) for 30 min at room temperature. All Abs used are listed in S1 Table. Stained cells were washed, fixed with FoxP3/Transcription Factor Buffer Set (ThermoFischer Scientific), and acquired on a BD FACS Symphony A3 (BD Biosciences). Samples were analyzed with FlowJo v.10 (TreeStar, Inc.) and quality control was performed with the flowAI algorithm [16]. Frequencies of CD69+CD40L+ of CD4+ T cells and CD69+41BB+ of CD8+ T cells were subtracted with each respective DMSO control. Negative values after subtraction were set to 0.001 as the limit of detection (LOD) to allow for logarithmic scale display in graphs. For each PBMC sample,

DMSO at the same concentration as in the respective peptide pools was used as a negative control and 1µg/ml SEB was used as a positive control.

Statistics

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

Statistical analysis was performed in Python (version 3.12.4) using SciPy (version 1.11.4) and scikit-posthocs (version 0.9.0). All plots and statistical annotations were generated using pandas (version 1.5.3), numpy (version 1.26.3), seaborn (version 0.13.2) and matplotlib (version 3.7.1) through custom scripts. Data distributions from flow cytometry experiments were determined to be non-parametric using diagnostic plots and the Shapiro-Wilk test for normality. For unpaired data, comparisons between three or more groups were analysed using the Kruskal-Wallis's test followed by the Dunn's post hoc test. For unpaired data between two groups, the Mann-Whitney rank test was used. Paired data were analysed using the Friedman test followed by Siegel and Castellan's All-Pairs Comparisons post hoc test. Post hoc test results were corrected using the Bonferroni method (adjusted alpha = 0.002 for comparisons between cohorts A and C, and adjusted alpha = 0.005 cohorts B, D and E). All tests were two-sided, with statistically significance set at p < 0.05. The adjusted p-value is reported in figures when correction for multiple comparisons was applied.

Results

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

Overview of vaccine cohorts

Out of the total 139 study subjects, clinical samples from 84 study subjects (12 randomly selected from each of the respective seven study cohorts A1, A2, B1, B2, C, D, and E) were selected for inclusion in the present study (Fig 1A and B). One study participant from cohort A1 was later excluded from all data analyses due to the detection of nAbs against TBEV at day 0, leaving 83 study subjects remaining in the present study. PBMCs were stimulated with overlapping peptide pools consisting of 15mers spanning the entire length of the two structural proteins envelope (E) and capsid (C), as well as the large and conserved non-structural protein-5 (NS5) (Fig 1C).

Kinetics of the antigen-specific CD4+ and CD8+ T cell vaccine response

First, we assessed antigen-specific T cell responses in the three cohorts that received TBEV (cohort C), JEV (cohort D), and YFV (cohort E) vaccines, respectively (Fig 2). CD4+ and CD8+ T cell responses were evaluated using an AIM assay (Fig 2A and S1 Fig). Significantly higher TBEV E- and C-specific CD4+ T cell responses were observed in the TBEV vaccinated cohort over time compared to baseline (Fig 2B). Similarly, significantly higher JEV E- and C-specific CD4+ T cell responses were observed over time compared to baseline (Fig 2C). In contrast, no detectable NS5-specific CD4+ T cell response was observed after vaccination with either TBEV or JEV vaccines (Fig 2B and C). Following YFV vaccination, YFV-specific CD4+ T cell responses were observed against both E, C, and NS5 (Fig 2D). The overall activation of antigen-specific CD8+ T cells was lower in participants who received the inactivated vaccines against TBEV (Fig 2E) and JEV (Fig 2F), while significant E- and NS5-specific CD8+ T cell responses were detected in participants who received the live attenuated YFV vaccine (Fig 2G). In summary, the AIM assay effectively captured the overall kinetics of the antigen-specific T cell response following vaccination with inactivated TBEV and JEV vaccines as well as with the live attenuated YFV flavivirus vaccine.

Co-vaccination retains the antigen-specific T cell response

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

Overall, the CD4+ and CD8+ T cell response against E epitopes was the most dominant antigen-specific T cell response across all vaccine cohorts (Fig 2). To evaluate the influence of concomitant delivery of vaccines on the antigen-specific T cell response, we compared the results from the single vaccinated TBEV, JEV, and YFV cohorts (cohorts C, D, and E) with those from the two co-vaccinated cohorts (cohorts A and B); the latter co-vaccinated with TBEV and YFV (TBEV+JEV) as well as JEV and YFV (JEV+YFV) vaccines, respectively (Fig 1). Initial analyses revealed similar kinetics in terms of CD4+ and CD8+ T cell responses in cohort A and cohort B, respectively (S2 Fig). Importantly, overall, no major differences in the magnitude of TBEV or JEV E-specific CD4+ T cell responses were observed when comparing the respective single and co-vaccinated cohorts (Fig 3A and B). Similar response patterns, though generally weaker than the CD4+ T cell responses, were observed among TBEV or JEV E-specific CD8+ T cells (Fig. 3C and D). Additionally, we investigated whether the YFV response was influenced by co-vaccination with TBEV or JEV vaccines. Overall, the observed YFV-specific T cell responses were similar (S3A Fig) or lower (S3B-D Fig) in the single vaccinated compared to the co-vaccinated cohorts, though the significance of this finding is not fully clear (see Discussion).

Co-vaccination in the same or different upper arm does not impact the antigenspecific T cell response

To determine whether concomitant delivery of the TBEV or JEV vaccines with the YFV vaccine affects immunogenicity depending on whether the vaccines were administered in the same or different upper arms, we analyzed specific subgroups of the covaccinated TBEV+YFV (cohort A1 and A2) and JEV+YFV (cohort B1 and B2) cohorts (Fig. 1). The frequency of TBEV E-specific CD4+ T cells was overall similar when the two TBEV+YFV subgroups were compared most apparent when evaluating results at the peak of responses and/or later timepoints (Fig 4A). Likewise, the frequency of JEV Especific CD4+ T cells was overall similar when the two JEV+YFV subgroups were compared (Fig 4B). Overall, analysis of the CD8+T cell responses yielded similar results

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

in terms of comparisons between groups vaccinated in the same or different upper arms (Fig 4C and Fig 4D), Additionally, the CD8+ T cell responses were overall weaker than CD4+ T cell responses, in line with our previous results (Figs 2 and 3). Similar patterns were observed for the YFV E-specific CD4+ and CD8+ T cell response, comparing corresponding groups (S4 Fig). Taken together, these data indicate that multiple immunizations in the same or different upper arms do not markedly influence the outcome the generation of CD4+ and CD8+ T cell responses. Effector memory T cells (T_{EM}) constitute the main memory phenotype of antigenspecific T cells We further investigated the phenotypical characteristics of the activated CD4+ and CD8+ T cells in the vaccine cohorts. The memory phenotypes studied for CD4+ and CD8+ T cells included central memory (T_{CM}, CCR7+CD45RA-), effector memory (T_{EM}, CCR7-CD45RA-), effector memory T cells re-expresses CD45RA (T_{EMRA}, CCR7-CD45RA+), as well as CD4+ T follicular helper cells (Tfh, CXCR5+). Across the studied cell populations, we observed an increase in the frequency of CD4+ T_{EM} cells following vaccination in the study cohorts (Fig 5 and S5 Fig). As a result, remaining populations, including Tfh cells, decreased in frequencies over time following vaccination (S5 Fig). The expansion of CD4+ T_{EM} cells follow as expected the initial expansion of AIM+ populations towards specific viral proteins as shown in Figs 2-4. These observations are in line with the notion that many of the above-mentioned CD4+ T cell populations, including T_{CM} and Tfh, may migrate to lymphoid tissues upon antigen activation [17]. The vaccine-induced T cell response showed limited cross-reactivity towards other flavivirus antigens Because similarities in amino acid sequences in viral proteins can drive cross-reactive immune responses between different viruses, we conducted multiple amino acid sequence alignments of the flaviviruses included in this study to characterize their overall sequence similarity. The E protein has 41-44% similarity when compared between TBEV, JEV, and YFV. The C protein has the lowest similarity, ranging from 24-

31% similarity, while the highest sequence similarity was seen within the NS5 protein with 61-63% similarity (Fig 6A). To address the extent to which T cell cross-reactivity among the flaviviruses studied exists, we compared TBEV, JEV, and YFV E-, C-, and NS5specific CD4+ and CD8+ T cell responses in all vaccine cohorts. With respect to E responses, we observed very limited cross-reactive T cell responses across all vaccine cohorts, including CD4+ (Fig 6B and C) and CD8+ T cell responses (Fig 6D and E). Similar results were also observed for CD4+ and CD8+ T cell responses against C (S6 Fig) and NS5 (S7 Fig). The results were further corroborated by analyses of increases in the median response on peak response days against the respective E, C, and NS5 antigens (S8-13 Figs). Taken together, these data demonstrate that the present flavivirus vaccines induce, at most, very limited cross-reactive T cell responses against each other.

Limited cross-reactivity against Zika virus antigens

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

Zika virus (ZIKV) also possesses amino acid sequence similarities with the other flaviviruses studied here (Fig S14A). This led to us to assess potential cross-reactivity to ZIKV antigens following vaccination with the present studied vaccines, with a particular focus on studies of cross-reactive responses elicited by the YFV vaccine. To this end, we did not detect any marked vaccine-induced CD4+ or CD8+ T cell reactivity against the ZIKV antigens (E, C, and NS5) in any of the three YFV, YFV+TBEV, or YFV+JEV vaccinated cohorts (Fig S14B-G).

Discussion

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

The present study presents findings from a non-randomized clinical trial cohort in which healthy study subjects received single or concomitant administrations of different flavivirus vaccines directed against TBEV, JEV, and YFV. Flow cytometry-based analysis revealed robust antigen-specific CD4+ and CD8+ T cell responses across all studied cohorts, with similar levels as single-vaccinated regardless of the concomitant vaccinedelivery or the site of administration. Additionally, the vaccines did not induce significant T cell cross-reactivity among each other or to ZIKV specific antigens. Vaccines remain the most effective interventions for many flavivirus-induced diseases [8]. Because of the general knowledge gap in relation to safety and immunogenicityrelated responses on concomitantly delivered vaccines [18], the recently conducted open label, non-randomized clinical trial was designed to provide safety and Ab immunogenicity-related data upon concomitant delivery of TBEV, JEV, and YFV vaccines [12]. However, the pivotal study did not address antigen-specific cellular immune responses. The present results complement the latter by showing that concomitant vaccine delivery does not markedly affect the generation of antigen-specific T cell responses, neither enhancing nor suppressing them. Additionally, immunization in the same or different upper arms did not largely impact the generation of antigen-specific T cell responses. The rationale for addressing the latter question was that local innate adjuvant-related effects from one vaccine might affect responses to the other vaccine, or that induction of specific immunity in the same local draining lymph nodes might skew the response towards one type of antigen over another. The recently reported binding and nAb-responses from the same study cohort [12] are in line with the abovementioned conclusions. However, notably, we did observe an indication of an increased YFV-specific T cell response in the co-vaccinated study participants compared to the single YFV-vaccinated study participants (S3 Fig). Further research is needed to assess the validity of this finding in a larger study cohort. The present study demonstrated marked CD4+ T cell responses in all vaccine cohorts, while CD8+ T cell responses were predominantly detected in the YFV vaccine recipients. It should be noted that the lower and more heterogenous detection of CD8+ T cells is

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

not unexpected with stimulation using 15-mer peptides. These observations are in line with earlier studies on T cell reactivity to YFV vaccination [19-21] and to more limited studies published with respect to T cell responses to TBEV [22-24] and JEV [25] vaccination. In this context, it has been described that alum-adjuvanted flavivirus vaccines induce more of a Th2-biased response and, in this, may avoid a more, sometimes immunopathological, Th1 and/or CD8+ T cell response [8]. The present study also mapped CD4+ and CD8+ T cell responses specifically against structural and nonstructural proteins from YFV, TBEV, JEV, and additionally ZIKV using overlapping peptide pools targeting the entire E, C, and NS5 proteins. While nAbs predominantly target the E protein [11, 26, 27], T cell responses can be directed against both structural and nonstructural flavivirus proteins [13, 28]. TBEV and JEV inactivated vaccine recipients predominantly showed responses to E and C, while live attenuated YFV vaccine recipients developed responses against all antigens, where the highest reactivities detected were against the E and NS5 antigens. Consistent with these observations, previous studies have shown that inactivated vaccines, such as those against TBEV and JEV, do not generate efficient T cell responses specific to NS proteins, resulting in lower CD8+ T cell activation and reduced immunogenicity compared to the live attenuated YFV vaccine [22, 24]. Several studies have addressed the role of pre-existing immunity upon flavivirus vaccination [29-38]. For example, in a study by Lima and collaborators, pre-existing immunity from prior JEV vaccination, but not YFV vaccination, was found to influence the duration of the CD4+ T cell response following vaccination with an inactivated ZIKV vaccine [39]. In relation to this, our longitudinal TBEV- and JEV-vaccination and consecutive sampling strategy also allowed for investigations of the influence of preexisting immunity from YFV vaccination on the T cell response to TBEV- and JEV-booster doses up to 210 and 60 days, respectively. Assessing the present data, we did not detect a significant enhancement or reduction in T cell responses towards TBEV or JEV epitopes in the YFV co-vaccinated groups, indicating that pre-existing immunity from YFV vaccination does not markedly influence the CD4+ and CD8+ T cell response to TBEV or JEV booster doses, at least not within the present study (rather short) period.

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

In relation to the discussion above, we also more specifically addressed potential T cell cross-reactivities between the vaccine-induced immune responses. In short, we found no evidence that vaccination with YFV, TBEV, or JEV alone or in combination resulted in any significant cross-reactive T cell response to viral antigens other than those specific to the vaccine used for vaccination. This included no detectable T cell responses against ZIKV virus epitopes. The present results align with those from a comprehensive study by Grifoni and colleagues [40]. In that study, vaccination with YFV-17D resulted in limited cross-reactive T cells against DENV, ZIKV, West Nile virus (WNV), and JEV antigens. Additionally, cross-reactive T cells were predominately seen against 9 or 10-mers with a sequence similarity above 67%. In line with the findings above, the lack of cross-reactive T cell responses in the present study can be explained by the relatively long antigenic distance between YFV, JEV, and TBEV, which correspond to three different serocomplexes. Furthermore, the YFV serocomplex has the highest genetic distance from other flavivirus serocomplexes, where most of the conserved T cell epitopes are lost [41]. Epidemiological studies further support the present conclusions. For example, no protective association was found between YFV antibody titers and protection against serious adverse outcomes from ZIKV exposure in utero [42]. In this context, it is noted that vaccination against YFV early on following the ZIKV outbreak in 2015 was suggested as a possible means to limit the severe consequences of ZIKV infection in the absence of a ZIKV-specific vaccine [43]. However, it cannot be excluded that responses to other combinations of flavivirus vaccines or combinations of vaccines from other vaccine platforms than the present ones studied could result in cross-reactive T cell responses [44]. The relative strength of the present study is that data were collected from a bona fide prospective clinical trial cohort with the scientific and regulatory rigor inherent to this design, including independent study monitoring of original clinical trial data. It complements recently published clinical safety and serological data from the same study cohort addressing the effects of concomitant delivery of different flavivirus vaccines [12]. With respect to the limitations of this study, larger study groups could have given even more robust data. Deeper analyses on responding T cell populations could have given more detailed insights into other characteristics of responding T cell

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

populations. Studies could have been performed also against other flavivirus antigens than E, C and NS5. The absence of screening for seropositivity to flavivirus exposure other than those the study subjects were vaccinated with prior to enrollment into the study is a relative limit. However, with respect to this, only two study participants with positive nAbs against TBEV and no one to JEV or YFV were identified among the entire cohort (n=139). One of these study subjects randomly picked for the present study had to be omitted from further analysis. Hence, the present study came to include 83 of the intended 84 study subjects. In conclusion, the present study, together with data from the previous clinical trial [12], underscores the development of robust Ab and T cell responses elicited by flavivirus vaccinations. The two studies support the safety and efficacy of simultaneous vaccine administration strategies with the herein studied flavivirus vaccines. These findings provide valuable insights into the optimization of vaccination protocols, highlighting the compatibility of different vaccination regimens with minimal impact on immune response quality and safety profiles. This is particularly important as the world becomes increasingly susceptible to flavivirus-caused diseases as a consequence of climate change facilitating the geographical expansion of insect vectors, habitat, and urban environmental changes, as well as extensive global traveling [6, 8].

491

492

493

494

495

496

497

498

499

500

Acknowledgments We gratefully acknowledge the contributions of all study participants in the original clinical trial. We also extend our appreciation to the Karolinska Trial Alliance staff and research nurses for their exceptional organization of participant recruitment, scheduling, vaccination, and clinical sampling. Special thanks go to R. Varnaité, J. Emgård, N. Al-Tawil, L. Lindquist, J. Klingström and K. Loré for their dedicated efforts and contributions to the original clinical trial. We are grateful to Y. Gao for providing methodological advice. Additionally, we thank E. Alici and D. Calder for their support during the initial phase of this project.

References

501

- 502 1. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV Virus
- 503 Taxonomy Profile: Flaviviridae. J Gen Virol. 2017;98(1):2-3. doi: 10.1099/jgv.0.000672.
- PubMed PMID: 28218572; PubMed Central PMCID: PMCPMC5370391.
- 505 2. World Health Organization: Yellow Fever 2024. Available from:
- 506 https://www.who.int/news-room/fact-sheets/detail/yellow-fever.
- 3. Riccardi N, Antonello RM, Luzzati R, Zajkowska J, Di Bella S, Giacobbe DR. Tick-
- 508 borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention,
- and treatment. Eur J Intern Med. 2019;62:1-6. Epub 20190122. doi:
- 510 10.1016/j.ejim.2019.01.004. PubMed PMID: 30678880.
- 511 4. Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and
- 512 future prospects. Ther Clin Risk Manag. 2015;11:435-48. Epub 20150319. doi:
- 513 10.2147/TCRM.S51168. PubMed PMID: 25848290; PubMed Central PMCID:
- 514 PMCPMC4373597.
- 515 5. Chong HY, Leow CY, Abdul Majeed AB, Leow CH. Flavivirus infection-A review of
- 516 immunopathogenesis, immunological response, and immunodiagnosis. Virus Res.
- 517 2019;274:197770. Epub 20191015. doi: 10.1016/j.virusres.2019.197770. PubMed PMID:
- 518 31626874.
- 519 6. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat
- 520 Microbiol. 2020;5(6):796-812. Epub 20200504. doi: 10.1038/s41564-020-0714-0.
- 521 PubMed PMID: 32367055; PubMed Central PMCID: PMCPMC7696730.
- 522 7. van den Elsen K, Chew BLA, Ho JS, Luo D. Flavivirus nonstructural proteins and
- replication complexes as antiviral drug targets. Curr Opin Virol. 2023;59:101305. Epub
- 524 20230302. doi: 10.1016/j.coviro.2023.101305. PubMed PMID: 36870091; PubMed
- 525 Central PMCID: PMCPMC10023477.
- 526 8. Rawle DJ, Hugo LE, Cox AL, Devine GJ, Suhrbier A. Generating prophylactic
- 527 immunity against arboviruses in vertebrates and invertebrates. Nat Rev Immunol.
- 528 2024;24(9):621-36. Epub 20240403. doi: 10.1038/s41577-024-01016-6. PubMed PMID:
- 529 38570719.
- 530 9. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine.
- 531 2012;30(29):4301-6. doi: 10.1016/j.vaccine.2011.09.114. PubMed PMID: 22682286.
- 532 10. Dutta SK, Langenburg T. A Perspective on Current Flavivirus Vaccine
- 533 Development: A Brief Review. Viruses. 2023;15(4). Epub 20230328. doi:
- 10.3390/v15040860. PubMed PMID: 37112840; PubMed Central PMCID:
- 535 PMCPMC10142581.
- 536 11. Orenstein WA, Offit PA, Edwards KM, Plotkin SA. Plotkin's vaccines. 8th edition.
- ed. Philadelphia, PA: Elsevier; 2024. xxiii, 1782 pages p.
- 538 12. Sandberg JT, Lofling M, Varnaite R, Emgard J, Al-Tawil N, Lindquist L, et al. Safety
- 539 and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne
- 540 encephalitis or Japanese encephalitis vaccines: Results from an open label, non-
- 541 randomized clinical trial. PLoS Negl Trop Dis. 2023;17(2):e0010616. Epub 20230209.
- doi: 10.1371/journal.pntd.0010616. PubMed PMID: 36758067; PubMed Central PMCID:
- 543 PMCPMC9946270.
- 544 13. Slon Campos JL, Mongkolsapaya J, Screaton GR. The immune response against
- 545 flaviviruses. Nature Immunology. 2018;19(11):1189-98. doi: 10.1038/s41590-018-0210-
- 546 3.

- 547 14. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable
- 548 generation of high-quality protein multiple sequence alignments using Clustal Omega.
- 549 Mol Syst Biol. 2011;7:539. Epub 20111011. doi: 10.1038/msb.2011.75. PubMed PMID:
- 21988835; PubMed Central PMCID: PMCPMC3261699.
- 551 15. Niessl J, Sekine T, Lange J, Konya V, Forkel M, Maric J, et al. Identification of
- resident memory CD8(+) T cells with functional specificity for SARS-CoV-2 in unexposed
- oropharyngeal lymphoid tissue. Sci Immunol. 2021;6(64):eabk0894. Epub 20211022.
- doi: 10.1126/sciimmunol.abk0894. PubMed PMID: 34519539; PubMed Central PMCID:
- 555 PMCPMC10763663.
- 556 16. Monaco G, Chen H, Poidinger M, Chen J, de Magalhaes JP, Larbi A. flowAl:
- automatic and interactive anomaly discerning tools for flow cytometry data.
- 558 Bioinformatics. 2016;32(16):2473-80. Epub 20160410. doi:
- 559 10.1093/bioinformatics/btw191. PubMed PMID: 27153628.
- 560 17. Lam N, Lee Y, Farber DL. A guide to adaptive immune memory. Nat Rev Immunol.
- 561 2024. Epub 20240603. doi: 10.1038/s41577-024-01040-6. PubMed PMID: 38831162.
- 562 18. Vaccine Recommendations and Guidelines of the ACIP 2024. Available from:
- 563 https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
- 564 19. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The
- 565 Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T
- 566 Cell Response. The Journal of Immunology. 2009;183(12):7919-30. doi:
- 567 10.4049/jimmunol.0803903.
- 568 20. James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW. Yellow fever
- vaccination elicits broad functional CD4+ T cell responses that recognize structural and
- 570 nonstructural proteins. J Virol. 2013;87(23):12794-804. Epub 20130918. doi:
- 571 10.1128/JVI.01160-13. PubMed PMID: 24049183; PubMed Central PMCID:
- 572 PMCPMC3838168.
- 573 21. Mateus J, Grifoni A, Voic H, Angelo MA, Phillips E, Mallal S, et al. Identification of
- Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees. Viruses. 2020;12(11). Epub
- 575 20201112. doi: 10.3390/v12111300. PubMed PMID: 33198381; PubMed Central PMCID:
- 576 PMCPMC7697718.
- 577 22. Varnaitė R, Blom K, Lampen MH, Vene S, Thunberg S, Lindquist L, et al.
- 578 Magnitude and Functional Profile of the Human CD4+ T Cell Response throughout
- 579 Primary Immunization with Tick-Borne Encephalitis Virus Vaccine. The Journal of
- 580 Immunology. 2020;204(4):914-22. doi: 10.4049/jimmunol.1901115.
- 581 23. Schwaiger J, Aberle JH, Stiasny K, Knapp B, Schreiner W, Fae I, et al. Specificities
- of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection:
- 583 correlation with structure and epitope prediction. J Virol. 2014;88(14):7828-42. Epub
- 584 20140430. doi: 10.1128/JVI.00196-14. PubMed PMID: 24789782; PubMed Central
- 585 PMCID: PMCPMC4097808.
- 586 24. Aregay A, Slunecko J, Korva M, Bogovic P, Resman Rus K, Knap N, et al. Tick-
- 587 borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody
- responses to non-structural proteins. NPJ Vaccines. 2024;9(1):141. Epub 20240807. doi:
- 589 10.1038/s41541-024-00936-7. PubMed PMID: 39112523; PubMed Central PMCID:
- 590 PMCPMC11306791.
- 591 25. Turtle L, Bali T, Buxton G, Chib S, Chan S, Soni M, et al. Human T cell responses to
- Japanese encephalitis virus in health and disease. Journal of Experimental Medicine.
- 593 2016;213(7):1331-52. doi: 10.1084/jem.20151517.

- 594 26. Hu T, Wu Z, Wu S, Chen S, Cheng A. The key amino acids of E protein involved in
- early flavivirus infection: viral entry. Virol J. 2021;18(1):136. Epub 20210703. doi:
- 596 10.1186/s12985-021-01611-2. PubMed PMID: 34217298; PubMed Central PMCID:
- 597 PMCPMC8254458.
- 598 27. Wu KP, Wu CW, Tsao YP, Kuo TW, Lou YC, Lin CW, et al. Structural basis of a
- 599 flavivirus recognized by its neutralizing antibody: solution structure of the domain III of
- the Japanese encephalitis virus envelope protein. J Biol Chem. 2003;278(46):46007-13.
- 601 Epub 20030902. doi: 10.1074/jbc.M307776200. PubMed PMID: 12952958.
- 602 28. Aberle JH, Koblischke M, Stiasny K. CD4 T cell responses to flaviviruses. J Clin
- 603 Virol. 2018;108:126-31. Epub 20181003. doi: 10.1016/j.jcv.2018.09.020. PubMed PMID:
- 604 30312909; PubMed Central PMCID: PMCPMC7611868.
- 605 29. Malafa S, Medits I, Aberle JH, Aberle SW, Haslwanter D, Tsouchnikas G, et al.
- 606 Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response
- in humans. PLoS Negl Trop Dis. 2020;14(2):e0008034. Epub 20200204. doi:
- 608 10.1371/journal.pntd.0008034. PubMed PMID: 32017766; PubMed Central PMCID:
- 609 PMCPMC7021315.
- 610 30. Santos-Peral A, Luppa F, Goresch S, Nikolova E, Zaucha M, Lehmann L, et al.
- Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive
- antibodies with potential to enhance dengue virus infection. Nat Commun.
- 613 2024;15(1):1696. Epub 20240224. doi: 10.1038/s41467-024-45806-x. PubMed PMID:
- 614 38402207; PubMed Central PMCID: PMCPMC10894228.
- 615 31. Bradt V, Malafa S, von Braun A, Jarmer J, Tsouchnikas G, Medits I, et al. Pre-
- existing yellow fever immunity impairs and modulates the antibody response to tick-
- borne encephalitis vaccination. NPJ Vaccines. 2019;4:38. Epub 20190906. doi:
- 618 10.1038/s41541-019-0133-5. PubMed PMID: 31508246; PubMed Central PMCID:
- 619 PMCPMC6731309.
- 620 32. Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, et al.
- 621 Immunogenicity and safety of concomitant and sequential administration of yellow fever
- 622 YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3
- 623 randomized, controlled study. PLoS Negl Trop Dis. 2023;17(3):e0011124. Epub
- 624 20230308. doi: 10.1371/journal.pntd.0011124. PubMed PMID: 36888687; PubMed
- 625 Central PMCID: PMCPMC9994689.
- 626 33. Sirivichayakul C, Biswal S, Saez-Llorens X, Lopez-Medina E, Borja-Tabora C, Bravo
- 627 L, et al. Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With
- 628 Prior Japanese Encephalitis or Yellow Fever Vaccination. J Infect Dis. 2024. Epub
- 629 20240429. doi: 10.1093/infdis/jiae222. PubMed PMID: 38682569.
- 630 34. Burgomaster KE, Foreman BM, Aleshnick MA, Larman BC, Gordon DN,
- 631 Maciejewski S, et al. Limited Flavivirus Cross-Reactive Antibody Responses Elicited by a
- 632 Zika Virus Deoxyribonucleic Acid Vaccine Candidate in Humans. J Infect Dis.
- 633 2021;224(9):1550-5. doi: 10.1093/infdis/jiab185. PubMed PMID: 33961055; PubMed
- 634 Central PMCID: PMCPMC8599923.
- 635 35. Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Curtis DJ, et al. Priming
- 636 with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition
- of multiple flaviviruses without boosting antibody responses induced by an inactivated
- 638 Zika virus vaccine. EBioMedicine. 2023;97:104815. Epub 20231002. doi:
- 639 10.1016/j.ebiom.2023.104815. PubMed PMID: 37793212; PubMed Central PMCID:
- 640 PMCPMC10562857.

- 641 36. Rossbacher L, Malafa S, Huber K, Thaler M, Aberle SW, Aberle JH, et al. Effect of
- 642 previous heterologous flavivirus vaccinations on human antibody responses in tick-
- borne encephalitis and dengue virus infections. J Med Virol. 2023;95(11):e29245. doi:
- 10.1002/jmv.29245. PubMed PMID: 38009693; PubMed Central PMCID:
- 645 PMCPMC10952712.
- 646 37. Saron WAA, Rathore APS, Ting L, Ooi EE, Low J, Abraham SN, et al. Flavivirus
- 647 serocomplex cross-reactive immunity is protective by activating heterologous memory
- 648 CD4 T cells. Sci Adv. 2018;4(7):eaar4297. Epub 20180704. doi: 10.1126/sciadv.aar4297.
- PubMed PMID: 29978039; PubMed Central PMCID: PMCPMC6031378.
- 650 38. Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, et al.
- 651 Concomitant or sequential administration of live attenuated Japanese encephalitis
- 652 chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II
- evaluation of safety and immunogenicity. Hum Vaccin. 2010;6(11):906-14. Epub
- 654 20101101. doi: 10.4161/hv.6.11.12854. PubMed PMID: 20864814; PubMed Central
- 655 PMCID: PMCPMC3060385.
- 656 39. Lima NS, Moon D, Darko S, De La Barrera RA, Lin L, Koren MA, et al. Pre-existing
- 657 Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus
- 658 Inactivated Vaccine. Front Immunol. 2021;12:640190. Epub 20210224. doi:
- 659 10.3389/fimmu.2021.640190. PubMed PMID: 33717194; PubMed Central PMCID:
- 660 PMCPMC7943459.
- 661 40. Grifoni A, Voic H, Dhanda SK, Kidd CK, Brien JD, Buus S, et al. T Cell Responses
- 662 Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-
- Reactivity with Other Flavivirus Species. Journal of Virology. 2020;94(10). doi:
- 664 10.1128/jvi.00089-20.
- 665 41. Dos Santos Franco L, Gushi LT, Luiz WB, Amorim JH. Seeking Flavivirus Cross-
- 666 Protective Immunity. Front Immunol. 2019;10:2260. Epub 20190920. doi:
- 667 10.3389/fimmu.2019.02260. PubMed PMID: 31616432; PubMed Central PMCID:
- 668 PMCPMC6763598.
- 669 42. Piauilino ICR, Souza R, Lima MT, Rodrigues YKB, da Silva LFA, Gouveia AS, et al.
- Does the Presence or a High Titer of Yellow Fever Virus Antibodies Interfere with
- 671 Pregnancy Outcomes in Women with Zika Virus Infection? Viruses. 2023;15(11). Epub
- 672 20231111. doi: 10.3390/v15112244. PubMed PMID: 38005922; PubMed Central PMCID:
- 673 PMCPMC10675107.

680

- 674 43. Blom K, Sandberg JT, Loré K, Ljunggren HG. Prospects for induction of CD8 T cell-
- 675 mediated immunity to Zika virus infection by yellow fever virus vaccination. Journal of
- 676 Internal Medicine. 2017;282(3):206-8. doi: 10.1111/joim.12638.
- 677 44. Rathore APS, St John AL. Cross-Reactive Immunity Among Flaviviruses. Front
- 678 Immunol. 2020;11:334. Epub 20200226. doi: 10.3389/fimmu.2020.00334. PubMed
- 679 PMID: 32174923; PubMed Central PMCID: PMCPMC7054434.

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

Figure Legends Fig 1. Overview of the vaccine cohorts (A) Blood sampling schedule and (B) administration sites for all vaccine cohorts included in the study. The number (n) of study participants in each vaccine cohort is written and applies to all subsequent Figs. (C) Out of the three structural and seven nonstructural proteins encoded by the flavivirus genome, capsid (C), envelope (E), and nonstructural protein-5 (NS5), were selected as targets for overlapping peptide poolgeneration. Peptides, 15-mers with 11 amino acid (aa) overlap, were pooled for the respective protein and the number of peptides for each pool indicated. Fig 2. Kinetics of the antigen-specific CD4+ and CD8+ T cell response in study participants vaccinated against TBEV, JEV, and YFV. (A) Representative flow cytometry gating for the AIM assay used to identify antigenspecific CD4+ T cells (CD69+CD40L+) and antigen-specific CD8+ T cells (CD69+41BB+) after PBMC stimulation with DMSO (negative control), SEB (positive control), and peptide pool (E, C or NS5). (B-D) Frequency of TBEV-, JEV- and YFV-specific E, C, and NS5 CD4+ T cells in the (B) TBEV (cohort C), (C) JEV (cohort D) and (D) YFV vaccinated (cohort E), respectively. (E-G) Frequency of TBEV-, JEV- and YFV-specific E, C, and NS5 CD8+ T cells in the (E) TBEV (cohort C), (F) JEV (cohort D) and (G) YFV vaccinated (cohort E), respectively. (D-G) Statistical analysis assessed by Friedman test, with Siegel and Castellan's All-Pairs Comparisons post hoc tests with Bonferroni correction. Significant results are shown, where: *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001, ***p \leq 0.0001. Fig 3. Influence of co-vaccination on antigen-specific CD4+ and CD8+ T cell responses.

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

(A) Frequency of TBEV E-specific CD4+ T cells between study participants from cohort C (TBEV) and cohort A (TBEV+YFV) and (B) frequency of JEV E-specific CD4+T cells between cohort D (JEV) and cohort B (JEV+YFV). (C) Frequency of TBEV E-specific CD8+ T cells between cohort C and cohort A and (D) frequency of JEV E-specific CD8+T cells between cohort D and cohort B. (A-D) Statistical analysis assessed by Mann-Whitney rank test at each time point. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. Fig 4. Influence of co-vaccination on antigen-specific T cell responses upon vaccination in the same or different upper arms. (A) Frequency of TBEV E-specific CD4+ T cells compared between cohort A1 and A2. (B) Frequency of JEV E-specific CD4+ T cells compared between cohort B1 and B2. (C) Frequency of TBEV E-specific CD8+ T cells compared between cohort A1 and A2. (D) Frequency of JEV E-specific CD8+ T cells compared between cohort B1 and B2. (A-D) Statistical analysis assessed by Mann-Whitney rank test at each time point. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$, **** $p \le 0.0001$. Fig 5. Kinetics of the antigen-specific CD4+ memory effector T cell (T_{EM}) responses. (A) Representative flow cytometry gating of memory CD4+ T cells based on CD45RA and CCR7 expression within bulk CD4+ T cells (left panel) and within CD69+CD40L+ of CD4+ T cells after peptide stimulation (right panel). (B) Frequency of TBEV E-, C- and NS5specific CD4+ T_{EM} cells in TBEV vaccinated (cohort C). (C) Frequency of TBEV E-, C- and NS5-specific CD4+ T_{EM} cells in YFV+TBEV vaccinated (cohort A). (D) Frequency of JEV E-, C- and NS5-specific CD4+ T_{EM} cells in JEV vaccinated (cohort D). (E) Frequency of JEV E-, C- and NS5-specific CD4+ T_{EM} cells in YFV+JEV vaccinated (cohort B). (F) Frequency of YFV E-, C- and NS5-specific CD4+ T_{EM} cells in YFV vaccinated (cohort E). (B-F) Statistical analysis assessed by Friedman test, with Siegel and Castellan's All-Pairs Comparisons

739

740

741

742

743

744

745

746

747

post hoc tests with Bonferroni correction. Significant results are shown, where: *p ≤ 0.05 , **p ≤ 0.01 , ***p ≤ 0.001 , ****p ≤ 0.0001 . Fig 6. Cross-reactive E-specific T cell responses in the vaccine cohorts. (A) Sequence alignments between TBEV, JEV, and YFV. Heatmaps are annotated according to percent of amino acid sequence similarity. (B-C) Frequency of TBEV, JEV, and YFV E-specific CD4+ T cells, and (D-E) TBEV, JEV, and YFV E-specific CD8+ T cells, in study participants from all vaccine cohorts expressed as fold change relative to day 0. Line plots show median and 95% confidence interval (shaded area).

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

Supporting information S1 Fig. Flow cytometry gating strategy for identification of AIM markers and memory phenotypes. Lymphocytes were gated followed by subsequent singlet gating. Cells were then gated as CD3⁺ and Dump⁻ (dead cells, CD19+ and CD14+). T cells were subdivided as either CD4⁺ or CD8⁺ cells. CD4+ T follicular helper cells were identified as CXCR5+. CD4+ and CD8+ (bulk) memory cell phenotypes were defined by CD45RA and CCR7 expression. CD4+ and CD8+ AIM+ cells were gated on bulk and non-naive cells (CCR7+CD45RA+). Antigen-specific T cells were identified with AIM markers, where antigen-specific CD4+ T cells were defined by CD69⁺CD40L⁺ and antigen-specific CD8+ T cells as CD69⁺41BB⁺. S2 Fig. Kinetics of the antigen-specific T cell response in cohort A and B. (A-B) Frequency of TBEV- and JEV-specific E, C, and NS5 CD4+ T cells in the (A) TBEV+YFV (cohort A) and (B) JEV+YFV (cohort B), respectively. (C-D) Frequency of TBEVand JEV-specific E, C, and NS5 CD8+ T cells in the (C) TBEV+YFV (cohort A) and (D) JEV+YFV (cohort B), respectively. (A-D) Statistical analysis assessed by Friedman test, with Siegel and Castellan's All-Pairs Comparisons post hoc tests with Bonferroni correction. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, **** $p \le 0.0001$. S3 Fig. Influence of co-vaccination on the YFV-specific T cell response. (A) Frequency of YFV E-specific CD4+ T cells between study participants from cohort E (YFV) and cohort A (TBEV+YFV) and (B) frequency of YFV E-specific CD4+T cells between study participants from cohort E and cohort B (JEV+YFV). (C) Frequency of YFV E-specific CD8+ T cells between study participants from cohort E and cohort A and (D) frequency of YFV E-specific CD8+ T cells between cohort E and cohort B. (A-D) Statistical analysis assessed by Mann-Whitney rank test at each time point. Distribution

of data points is determined by boxplot with median and 25th-75th percentiles; whiskers

776 are drawn from 1.5 times the IOR. Significant results are shown, where: *p \leq 0.05, ** $p \le 0.01$, *** $p \le 0.001$, **** $p \le 0.0001$. 777 778 779 S4 Fig. Influence of co-vaccination on YFV E-specific T cell responses upon 780 vaccination in the same or different upper arms. 781 (A) Frequency of YFV E-specific CD4+ T cells compared between cohort A1 and A2. (B) 782 Frequency of YFV E-specific CD4+ T cells compared between cohort B1 and B2. (C) 783 Frequency of YFV E-specific CD8+ T cells compared between cohort A1 and A2. (D) 784 Frequency of YFV E-specific CD8+ T cells compared between cohort B1 and B2. (A-D) 785 Statistical analysis assessed by Mann-Whitney rank test at each time point. Distribution 786 of data points is determined by boxplot with median and 25th-75th percentiles; whiskers 787 are drawn from 1.5 times the IQR. Significant results are shown, where: *p ≤ 0.05, 788 ** $p \le 0.01$, *** $p \le 0.001$, **** $p \le 0.0001$. 789 790 S5 Fig. Distribution of antigen-specific T cell memory phenotypes and Tfh cells. 791 (A-E) Frequencies of T_{EM}, T_{CM}, T_{EMRA}, naive and Tfh of CD69+CD40L+ among CD4+ T cells 792 for cohort C, A, D, B and E, respectively. Frequencies represents proportions of the total 793 indicated populations. (F-J) Frequencies of T_{EM}, T_{CM}, T_{EMRA}, and naive of CD69+41BB+ 794 among CD8+ T cells for cohort C, A, D, B and E, respectively. Frequencies represents proportions of the total CD69+41BB+ among CD8+T cell population. 795 796 797 S6 Fig. Crossreactive C-specific T cell responses in the vaccine cohorts. 798 (A-B) Frequency of TBEV, JEV, and YFV C-specific CD4+ T cells and (C-D) TBEV, JEV, and 799 YFV C-specific CD8+ T cells in study participants from all cohorts expressed as fold 800 change relative to day 0. Line plots show median and 95% confidence interval (shaded 801 area). 802

S7 Fig. Crossreactive NS5-specific T cell responses in the vaccine cohorts.

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

(A-B) Frequency of TBEV, JEV, and YFV (NS5-specific CD4+ T cells and (C-D) TBEV, JEV, and YFV NS5-specific CD8+ T cells in study participants from all cohorts expressed as fold change relative to day 0. Line plots show median and 95% confidence interval (shaded area). S8 Fig. Comparisons of cross-reactive E-specific CD4+ T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV E-specific CD4+ T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S9. Fig. Comparisons of cross-reactive E-specific CD8+ T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV E-specific CD8+T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S10. Fig. Comparisons of cross-reactive C-specific CD4+ T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV C-specific CD4+ T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction.

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S11. Fig. Comparisons of cross-reactive C-specific CD8+ T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV C-specific CD8+T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S12. Fig. Comparisons of cross-reactive NS5-specific CD4+ T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV NS5-specific CD4+ T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction. Distribution of data points is determined by boxplot with median and 25th-75th percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S13. Fig. Comparisons of cross-reactive NS5-specific CD8+T cell responses in the vaccine cohorts. (A-B) Frequency of TBEV NS5-specific CD8+T cells in (A) cohorts C, D and E and (B) in cohorts A and B, expressed as fold change relative to day 0. (A-B) Statistical analysis assessed by Kruskal-Wallis's and post hoc Dunn's tests with Bonferroni correction. Distribution of data points is determined by boxplot with median and 25th-75th

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

percentiles; whiskers are drawn from 1.5 times the IQR. Significant results are shown, where: $p \le 0.05$, $p \le 0.01$, $p \le 0.001$, $p \le 0.001$, $p \le 0.0001$. S14 Fig. YFV vaccine-induced T cell response shows limited cross-reactivity with ZIKV antigens. (A) Sequence alignments between TBEV, JEV, YFV and ZIKV. Heatmaps are annotated according to percent of amino acid sequence similarities. (B) Frequency of ZIKV E, Cand NS5-specific CD4+ T cells in cohort A expressed as fold change relative to day 0. (C) Frequency of ZIKV E, C- and NS5-specific CD4+ T cells in cohort B expressed as fold change relative to day 0. (D) Frequency of ZIKV E, C- and NS5-specific CD4+ T cells in cohort E expressed as fold change relative to day 0. (E) Frequency of ZIKV E, C- and NS5specific CD8+ T cells in cohort A expressed as fold change relative to day 0. (F) Frequency of ZIKV E, C- and NS5-specific CD8+ T cells in cohort B expressed as fold change relative to day 0. (G) Frequency of ZIKV E, C- and NS5-specific CD8+T cells in cohort E expressed as fold change relative to day 0. (B-G) Line plots show median and 95% confidence interval (shaded area).













